P2371

Pamidronate disodium salt hydrate

≥95% (NMR), solid

• Synonym(e): 3-Amino-1-hydroxy-1-phosphonopropanephosphonic acid disodium salt hydrate
• Empirische Formel (Hill-System): C₃H₉NO₇P₂Na₂ · xH₂O
• CAS-Nummer: 57248-88-1
• Molekulargewicht: 279.03 (anhydrous basis)
• EG-Nummer: 260-647-1
• MDL-Nummer: MFCD11045314
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 24724574
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥95% (NMR)
• Form: solid
• Farbe: white
• mp (Schmelzpunkt): 300 °C
• Löslichkeit: H₂O: 28 mg/mL
• Ersteller: Novartis
• Lagertemp.: 2-8°C
• SMILES String: O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O
• InChI: 1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2
• InChIKey: TVQNUQCYOOJTMK-UHFFFAOYSA-L

Beschreibung

Biochem./physiol. Wirkung

Pamidronate disodium has the ability to block Wnt and β-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth.

Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC₅₀ = 200 nM).

Leistungsmerkmale und Vorteile

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• H-Sätze: H302
• P-Sätze: P264 - P270 - P301 + P312 - P501
• Gefahreneinstufungen: Acute Tox. 4 Oral
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: dust mask type N95 (US), Eyeshields, Gloves